Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study
Latest Information Update: 09 Jun 2024
At a glance
- Drugs VLA 15 (Primary) ; Alum
- Indications Lyme disease
- Focus Pharmacodynamics
- Sponsors Pfizer; Valneva
- 03 Jun 2024 According to a Valneva media release, companies aim to publish The Lancet results in a peer-reviewed medical journal.
- 03 Jun 2024 According to a Valneva media release, today announced that the results of two Phase 2 clinical trials (VLA15-201 and VLA15-202) of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.